Myeloid-derived suppressor cells in cancer patients

A clinical perspective

Alberto J. Montero, Claudia Marcela Diaz-Montero, Christos E. Kyriakopoulos, Vincenzo Bronte, Susanna Mandruzzato

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively investigated in preclinical models, especially in the context of cancer. One of the major obstacles in their accurate identification has been the definition of an unambiguous phenotype, shared between mice and humans, and clearly correlating with their suppressive function. In this paper, we review the literature concerning the phenotype in mouse and in humans, showing that at least 2 subsets of MDSCs are present under different situations. We also address the role of MDSCs in tumor progression, evaluate the prognostic significance of MDSC in cancer patients, and their possible role as marker of clinical outcome and response to therapy. Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies.

Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalJournal of Immunotherapy
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Neoplasms
Phenotype
Myeloid Cells
Biomarkers
Myeloid-Derived Suppressor Cells
Therapeutics

Keywords

  • myeloid cells
  • myeloid-derived suppressor cells
  • suppression

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

Myeloid-derived suppressor cells in cancer patients : A clinical perspective. / Montero, Alberto J.; Diaz-Montero, Claudia Marcela; Kyriakopoulos, Christos E.; Bronte, Vincenzo; Mandruzzato, Susanna.

In: Journal of Immunotherapy, Vol. 35, No. 2, 02.2012, p. 107-115.

Research output: Contribution to journalArticle

Montero, Alberto J. ; Diaz-Montero, Claudia Marcela ; Kyriakopoulos, Christos E. ; Bronte, Vincenzo ; Mandruzzato, Susanna. / Myeloid-derived suppressor cells in cancer patients : A clinical perspective. In: Journal of Immunotherapy. 2012 ; Vol. 35, No. 2. pp. 107-115.
@article{44ed0b20236543ed9aedbd58153165f7,
title = "Myeloid-derived suppressor cells in cancer patients: A clinical perspective",
abstract = "Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively investigated in preclinical models, especially in the context of cancer. One of the major obstacles in their accurate identification has been the definition of an unambiguous phenotype, shared between mice and humans, and clearly correlating with their suppressive function. In this paper, we review the literature concerning the phenotype in mouse and in humans, showing that at least 2 subsets of MDSCs are present under different situations. We also address the role of MDSCs in tumor progression, evaluate the prognostic significance of MDSC in cancer patients, and their possible role as marker of clinical outcome and response to therapy. Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies.",
keywords = "myeloid cells, myeloid-derived suppressor cells, suppression",
author = "Montero, {Alberto J.} and Diaz-Montero, {Claudia Marcela} and Kyriakopoulos, {Christos E.} and Vincenzo Bronte and Susanna Mandruzzato",
year = "2012",
month = "2",
doi = "10.1097/CJI.0b013e318242169f",
language = "English",
volume = "35",
pages = "107--115",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Myeloid-derived suppressor cells in cancer patients

T2 - A clinical perspective

AU - Montero, Alberto J.

AU - Diaz-Montero, Claudia Marcela

AU - Kyriakopoulos, Christos E.

AU - Bronte, Vincenzo

AU - Mandruzzato, Susanna

PY - 2012/2

Y1 - 2012/2

N2 - Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively investigated in preclinical models, especially in the context of cancer. One of the major obstacles in their accurate identification has been the definition of an unambiguous phenotype, shared between mice and humans, and clearly correlating with their suppressive function. In this paper, we review the literature concerning the phenotype in mouse and in humans, showing that at least 2 subsets of MDSCs are present under different situations. We also address the role of MDSCs in tumor progression, evaluate the prognostic significance of MDSC in cancer patients, and their possible role as marker of clinical outcome and response to therapy. Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies.

AB - Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively investigated in preclinical models, especially in the context of cancer. One of the major obstacles in their accurate identification has been the definition of an unambiguous phenotype, shared between mice and humans, and clearly correlating with their suppressive function. In this paper, we review the literature concerning the phenotype in mouse and in humans, showing that at least 2 subsets of MDSCs are present under different situations. We also address the role of MDSCs in tumor progression, evaluate the prognostic significance of MDSC in cancer patients, and their possible role as marker of clinical outcome and response to therapy. Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies.

KW - myeloid cells

KW - myeloid-derived suppressor cells

KW - suppression

UR - http://www.scopus.com/inward/record.url?scp=84856899903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856899903&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e318242169f

DO - 10.1097/CJI.0b013e318242169f

M3 - Article

VL - 35

SP - 107

EP - 115

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 2

ER -